ClinicalTrials.gg

Program

efpeglenatide

Also written as “HM11260C”, “Efpeglenatide SAR439977” and “efpeglenatide (SAR439977)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by 2 companies.

Furthest: phase 3, since Nov 21, 201713 company-led studies, 1 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical91 open or runningphase 3since Nov 21, 2017Mar 23, 2010Nov 2027phase 3 · NCT07379333
Sanofi40 open or runningphase 3since Apr 5, 2018Apr 5, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2010First study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01093729 · 41 enrolled
  2. Oct 4, 2011Phase 2 study in Diabetes MellitusHanmi Pharmaceutical · NCT01452451 · 72 enrolled · United States
  3. Jan 30, 2014Phase 2 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT02057172 · 254 enrolled · United States
  4. Feb 5, 2014Phase 1 study in Diabetes MellitusHanmi Pharmaceutical · NCT02059564 · 44 enrolled · United States
  5. Feb 24, 20142 phase 2 studiesHanmi Pharmaceutical · NCT02081118, NCT02075281
  6. Nov 21, 2017Phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT03353350 · 406 enrolled · United States, Germany, Poland and more
  7. Apr 5, 2018Sanofi's first study: phase 3 study in Diabetes Mellitus, Type 2New to SanofiSanofi · NCT03496298 · 4,076 enrolled · United States, Argentina, Bulgaria and more
  8. Sep 24, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03684642 · 908 enrolled · United States, Hungary, Poland and more
  9. Oct 18, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03713684 · 370 enrolled · United States, China, Korea, Republic of
  10. Dec 7, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03770728 · 312 enrolled · United States, China, Taiwan
  11. Dec 8, 2023Phase 3 study in ObesityHanmi Pharmaceutical · NCT06174779 · 448 enrolled · South Korea
  12. Jan 23, 2026Phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT07379333 · 118 planned · South Korea

Ahead

  1. Nov 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Hanmi Pharmaceutical · NCT07379333

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07379333Diabetes Mellitus, Type 2 · South Korea3RecruitingHanmi PharmaceuticalNov 2027118
NCT06174779Obesity · South Korea3CompletedHanmi PharmaceuticalAug 14, 2025448
NCT03770728Diabetes Mellitus, Type 2 · United States, China, Taiwan3TerminatedSanofiNov 28, 2020312
NCT03713684Diabetes Mellitus, Type 2 · United States, China, Korea, Republic of3TerminatedSanofiNov 20, 2020370
NCT03684642Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more3TerminatedSanofiOct 13, 2020908
NCT03496298Diabetes Mellitus, Type 2 · United States, Argentina, Bulgaria and more3TerminatedSanofiDec 10, 20204,076
NCT03353350Diabetes Mellitus, Type 2 · United States, Germany, Poland and more3CompletedHanmi PharmaceuticalJan 29, 2020406
NCT02075281Obesity · United States2CompletedHanmi PharmaceuticalJan 2015297
NCT02081118Diabetes Mellitus, Type 2 · United States2CompletedHanmi PharmaceuticalMar 2015209
NCT02059564Diabetes Mellitus · United States1UNKNOWNHanmi PharmaceuticalOct 201444
NCT02057172Diabetes Mellitus, Type 2 · United States2CompletedHanmi PharmaceuticalOct 2014254
NCT01452451Diabetes Mellitus · United States2CompletedHanmi PharmaceuticalJun 201372
NCT01093729Healthy1CompletedHanmi PharmaceuticalOct 201041

How it is read

Names in the registry

  • “HM11260C”, 12 entries
  • “Efpeglenatide SAR439977”, 2 entries
  • “efpeglenatide (SAR439977)”, 1 entry
  • “Efpeglenatide”, 1 entry
  • “Efpeglenatide (SAR439977)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.